Canopy Growth (CGC) Change in Receivables (2019 - 2025)
Canopy Growth (CGC) reported Change in Receivables of -$14.1 million for Q4 2025, down 378.38% on a YoY basis from $5.1 million in Q4 2024, and down 568.28% sequentially from -$2.1 million in Q2 2025.
Canopy Growth (CGC) Change in Receivables (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Change in Receivables data on file, last reported at -$14.1 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 378.38% year-over-year to -$14.1 million; the trailing twelve-month figure through Dec 2025 stood at -$13.5 million (down 134.36% YoY), and the FY2026 full-year result was -$18.7 million, down 699.22% from the prior year.
- Change in Receivables retreated to -$14.1 million in Q4 2025, from -$2.1 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $15.2 million in Q2 2023 to a low of -$14.1 million in Q4 2025.
- A 5-year average of -$1.6 million and a median of -$1.4 million in 2025 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables sank 2250.97% in 2022 and soared 612.35% in 2023, its largest moves.
- Tracing CGC's Change in Receivables over 5 years: stood at $6.6 million in 2021, then plunged by 111.71% to -$768381.2 in 2022, then soared by 248.84% to $1.1 million in 2023, then jumped by 341.59% to $5.1 million in 2024, then slumped by 378.38% to -$14.1 million in 2025.
- Business Quant data shows CGC's Change in Receivables at -$14.1 million in Q4 2025, -$2.1 million in Q2 2025, and $5.1 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.06 Mn |
| Dec 31, 2025 | -14.06 Mn |
| Jun 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -2.10 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -488,401.89 |
| Jun 30, 2024 | -488,401.89 |
| Mar 31, 2024 | -7.95 Mn |
| Mar 31, 2024 | -7.95 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | -5.60 Mn |
| Sep 30, 2023 | -5.60 Mn |
| Jun 30, 2023 | 15.19 Mn |
| Jun 30, 2023 | 15.19 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Mar 31, 2023 | 5.10 Mn |